Volunteer Assignments and Opportunities: Difference between revisions
| [unchecked revision] | [unchecked revision] |
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
!Notes | !Notes | ||
|- | |- | ||
|'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''|| | |'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''||Mark Evans, Fabiola Quintero-Rivera | ||
|Fabiola Quintero-Rivera (FQR) | |||
| | | | ||
| | | | ||
| Line 84: | Line 85: | ||
| | | | ||
|- | |- | ||
|'''''Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2'''''||'''''Overview'''''|| | |'''''Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2'''''||'''''Overview'''''||Daynna J.Wolff | ||
|FQR | |||
| | | | ||
| | | | ||
| Line 107: | Line 109: | ||
| | | | ||
|- | |- | ||
| Myeloid/Lymphoid Neoplasms with PCM1-JAK2||Disease|| | | Myeloid/Lymphoid Neoplasms with PCM1-JAK2||Disease||Daynna J.Wolff | ||
|FQR | |FQR | ||
|PENDING | |PENDING | ||